Business
INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update
Conference Call Today at 4:30pm ETBOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces its financial results for the quarter ended March 31, 2025 and provides a business update. Q1 2025 and Recent Corporate Highlights DN-TNF Platform Highlights (XPro™): Top-line results from the MINDFuL phase 2 trial in Alzheimer’s expected i
About this update from Inmune Bio Inc.
[{"type":"image","alt":"INmune Bio, Inc.","displaySize":"","headline":null,"caption":"INmune Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":82,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/b1e094e63c3b156eab453d7533cada9b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ESFQnG17m_59Q1hSBmvAug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b1e094e63c3b156eab453d7533cada9b","width":82,"height":60}},"lazy":false},{"type":"text","content":"Conference Call Today at 4:30pm ET","length":34,"tagName":"p"},{"type":"text","content":"BOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces its financial results for the quarter ended March 31, 2025 and provides a business update.","length":321,"tagName":"p"},{"type":"text","content":"Q1 2025 and Recent Corporate Highlights ","length":54,"tagName":"p"},{"type":"text","content":"DN-TNF Platform Highlights (XPro™):","length":35,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Top-line results from the MINDFuL phase 2 trial in Alzheimer’s expected in the second half of June.","length":99,"tagName":"p"}]},{"val":[{"type":"text","content":"Presented baseline demographics and disease profiles of participants in the MINDFuL phase II study at the annual International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders.","length":211,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":310,"olType":false},{"type":"text","content":"CORDStrom™ Platform:","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Announced plans to submit a Biologics License Application (BLA) with the FDA seeking approval of CORDStrom for treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB).","length":174,"tagName":"p"}]},{"val":[{"type":"text","content":"Received a favorable written opinion from The United States Patent and Trademark Office (USPTO), acting as the International Search Authority, on all claims in INmune Bio’s international patent application PCT/US25/17028, titled “THERAPEUTIC COMPOSITIONS COMPRISING POOLED, CULTURE-EXPANDED ...